Bipartisan senators are calling for a hearing into how the Medicare program could, or even should, cover an expensive new Alzheimer's drug with questionable benefit.

Sens. Elizabeth Warren (D-Mass.) and Bill Cassidy (R-La.) want the Senate Finance Committee to examine the challenges facing Medicare that were brought about by the Food and Drug Administration's (FDA) decision to approve Biogen's Aduhelm.

...

Read the full article here.